UNSPSC 51313100: Antihistamine or H1 blocker piperazines

Antihistamine or H1 blocker drugs made from organic compounds composed of a six-membered ring containing two nitrogen atoms at opposite positions (hexa-hydro-pyrazine(s)).

UNSPSC 51313100 Antihistamine or H1 blocker piperazines is a Class code that encompasses pharmaceutical products and drug-delivery systems procured by state and local health agencies, but recent solicitations show minimal activity directly aligned with this specific therapeutic classification. The recent opportunities tagged to this code reflect a broader pattern of state and local pharmaceutical procurement, including naloxone and drug-deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical supply agreements. Issuing bodies soliciting pharmaceutical products and services include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). The code shows sporadic activity rather than a sustained procurement stream for this particular drug class.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (IFB60459723LAS, due Jul 26, 2023) to procure 1,900 units of naloxone and 800 safe drug-deactivation systems annually with quarterly deliveries, structured as a two-year contract with a one-year renewal option and requiring shipping included in pricing. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted Apr 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for establishing direct contracting relationships outside traditional pharmacy benefit managers and group purchasing organizations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP (S1070000015802, due Mar 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with evaluations weighted 75 percent on price competitiveness and requiring compliance with cGMP and Drug Supply Chain Security Act standards. The code does not show established concentration among repeat buyers; activity appears episodic and geographically dispersed across state and regional procurement entities.